Harnessing Antisense & RNA Chemistry to Target Undruggable CNS Diseases

Heralding a New Era of CNS-Targeted Oligonucleotides to the Clinic and Beyond

Uniting CNS Biotech & Pharma to Fuel the Next Wave of Oligonucleotide Drug Discovery, Translation & Clinical Progress

With Biogen’s milestone approval of Tofersen leading the charge with a first-in-class clinically effective ASO for ALS, the glass ceiling of efficacious and safe oligonucleotides for CNS indications has truly been shattered

The 4th Oligonucleotides for CNS Summit is the only forum wholly dedicated to unique challenges and neuroscience innovation for this modality, delving into the hottest ASO, siRNA, saRNA, and miRNA program updates and the latest industry challenges.

This July, join 150+ senior industry leaders across discovery biology, structural chemistry, preclinical, clinical, CMC, and regulatory this year from Roche, IONIS, Janssen, Merck, Novartis, Genentech, Creyon Bio, Stoke Therapeutics, Dyne Therapeutics and many more….

Access the comprehensive agenda, speaker line-up and

pre-conference focus days.

World-Class Speaker Faculty Includes:

Previously Attending Companies Include:

2024 Partners:

ChemGenes logo
SynOligo Biotechnologies, Oligonucleotides for CNS
Atuka, 4th Oligonucleotides for CNS Summit 2024

Top Testimonials:

Other Events in the World CNS Series: